根据SEC文件显示，市值68.9亿美元的医疗诊断公司Lantheus Holdings, Inc.（NASDAQ:LNTH）董事Mary Anne ...

2025年3月4日周二，Lantheus Holdings Inc（纳斯达克股票代码：LNTH）在TD Cowen第45届年度医疗保健会议上发表演讲，概述了公司在放射性药物领域提升患者治疗效果的战略重点。公司强调了其雄心勃勃的增长计划，包括潜在的收购和新产品上市，同时也认识到竞争压力和市场动态。

Analysts raise price forecasts. Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio Lantheus strengthens its radiopharmaceutical ...

Strategic acquisitions, including Life Molecular Imaging and Evergreen Theragnostics, have diversified Lantheus' pipeline, targeting new markets like Alzheimer's diagnostics and oncology therapeutics.

(Lantheus or the Company ... the agreements to acquire Life Molecular and Evergreen Theragnostics. Both acquisitions are expected to close in the second half of 2025, subject to customary ...

Brian Markison, CEO Evergreen Theragnostics is expected to add Octevy, a registrational stage PET radiodiagnostic that would complement Lantheus' therapeutic candidate, PNT2003. Both acquisitions ...

Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) jumped 19.8% in the morning session after the company delivered strong fourth-quarter 2024 results, with revenue and earnings ...